0001733413 false 0001733413 2022-05-11 2022-05-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares











Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934


Date of report (Date of earliest event reported): May 11, 2022





(Exact Name of Registrant as Specified in Its Charter)




Delaware   001-39102   82-4344737
(State or Other Jurisdiction
of Incorporation)
  (Commission File Number)   (I.R.S. Employer
Identification Number)


1751 River Run, Suite 400

Fort Worth, Texas 76107

(Address of principal executive offices)



(Registrant’s telephone number, including area code)


(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions.


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.


Securities registered pursuant to Section 12(b)of the Act:


Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock: Par value $.001   TFFP   Nasdaq Global Market







Item 2.02 Results of Operations and Financial Condition.


On May 11, 2022, TFF Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2022. A copy of the press release is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference.


The information in this Item 2.02, including the press release attached as Exhibit 99.1 hereto, is furnished pursuant to Item 2.02 but shall not be deemed “filed” for any purpose, including for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.


Item 9.01 Financial Statements and Exhibits


(d) Exhibits Method Filing


The following exhibit is furnished with this report:


Exhibit 99.1   Press release dated May 11, 2022 regarding the Registrant’s financial results for its fiscal quarter ended March 31, 2022.   Filed Electronically herewith
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)    







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: May 11, 2022 /s/ Kirk Coleman
  Kirk Coleman,
  Chief Financial Officer







TFF Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update


Announced Collaboration with Catalent to Further Expand Thin Film Freezing Applications with a Focus on Biologic Drug Development


Announced Second CRADA Agreement with USAMRIID and Geneva Foundation to Develop Novel Therapies Using Thin Film Freezing to Combat SARS-CoV-2, Ebola, and Marburg Viruses


Initiated Phase 2 Trials of Inhaled Voriconazole Powder and Inhaled Tacrolimus Powder With Interim Data for Each Program Expected Later in 2022


Significant Progress Made in Inhaled Niclosamide Powder Program Multiple Abstracts Highlighting Applications of Thin Film Freezing Presented at


Respiratory Drug Delivery (RDD) Meeting


Conference Call and Webcast Scheduled Today, Wednesday, May 11, 2022 at 4:30 PM ET


FORT WORTH, TX -- May 11, 2022 --TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported financial results for the first quarter of 2022 and provided an update on recent corporate and clinical developments. The Company will discuss the highlights on a conference call and webcast, scheduled for today, Wednesday, May 11, 2022, at 4:30 PM ET.


“During the first quarter, we made solid progress in expanding existing collaborations and forging new partnerships,” said Glenn Mattes, CEO of TFF Pharmaceuticals. “Most notably, we announced a strategic collaboration with Catalent that will enable their customers to gain access to our Thin Film Freezing technology, with an emphasis on applications in biologic drug development. We also expanded our activities with USAMRIID and the Geneva Foundation by signing a second CRADA agreement that will utilize our Thin Film Freezing technology to optimize the formulation of new, development-stage therapeutics aimed at combating exceptionally dangerous viruses, including SARS-CoV-2, Ebola, and Marburg. Based upon the robust pace of our ongoing partnering discussions, we remain confident that 2022 will see TFF pharmaceuticals enter into new collaborations while expanding many of our existing partnerships.


“With respect to our pipeline development, we made considerable progress across several programs during the quarter. We initiated Phase 2 studies for our Inhaled Voriconazole Powder and Inhaled Tacrolimus Powder, and we anticipate interim readouts for both trials later in the year. With each program having the potential to meaningfully advance the current standard of care in their respective indications, we believe positive readouts are likely to attract significant partnership interest.





The Inhaled Niclosamide Powder program has also made important progress. In April, we announced positive safety and pharmacokinetic data from a Phase 1 study, demonstrating that Niclosamide Inhalation Powder was well tolerated with no serious adverse events across all subject cohorts. We believe the Niclosamide program is yet another example of how Thin Film Freezing technology can be successfully applied in the clinic to deliver efficacious levels of drug more safely to patients.


“In early May, we were pleased to announce that Dr. Bill Williams, co-inventor of the Thin Film Freezing technology, and several of his colleagues from the University of Texas at Austin presented five abstracts at this year’s Respiratory Drug Delivery meeting related to applications of Thin Film Freezing. We believe this body of research underscores the unique and versatile nature of Thin Film Freezing technology and provides us with even more confidence that the pharmaceutical applications of our technology platform will only continue to grow over time.


“As our platform continues to expand, TFF is also making the appropriate level of investment to recruit exceptional talent to help manage this growth. During the quarter, we announced the appointment of Anthony Hickey, Ph.D. as Chief Scientific Officer and Brandi Roberts to our Board of Directors. We also made senior level appointments in key areas of our business, including product manufacturing, government and strategic initiatives, and regulatory affairs.


“The advancement of our internal pipeline candidates such as Inhaled Voriconazole and Tacrolimus Powder programs, coupled with the robust pace of ongoing partnering activity, strengthens our belief that our continued investment in Thin Film Freezing will translate into significant commercial success and value for our shareholders.”


Conference Call and Webcast Information


The Company will host a conference call today, Wednesday, May 11, 2022, at 4:30 PM, Eastern Time, to review the clinical, corporate and financial highlights. To participate in the conference call, please dial the following numbers prior to the start of the call:


Domestic Dial-In Number: Toll-Free: 1-844-825-9789


International Dial-In Number: 1-412-317-5180


Conference ID: 10166801


The call will also be broadcast live over the Web and can be accessed on TFF Pharmaceuticals’ Website, https://tffpharma.com or directly at https://viavid.webcasts.com/starthere.jsp?ei=1546904&tp_key=ca1cf4dc0b


Please access the Company’s website at least 15 minutes ahead of the conference to register, download, and install any necessary audio software. The conference call will also be available for replay for one month on the Company’s website in the Events Calendar of the Investors section.




Recent Clinical and Corporate Highlights:


Board of Director Appointment: In March, the Company announced the appointment of Brandi Roberts to the TFF Pharmaceuticals’ Board of Directors. Ms. Roberts has over 25 years of public accounting and finance experience, including 22 years at publicly traded pharmaceutical, medical technology, and life science companies. Ms. Roberts has served as the Chief Financial Officer of Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH) since January 2021. Previously, Ms. Roberts served as Chief Financial Officer of Lineage Cell Therapeutics, Inc. (NYSE: LCTX) from January 2019 to January 2021. Prior to joining Lineage, she served as Chief Financial Officer of REVA Medical, Inc. Ms. Roberts previously served as Chief Financial Officer of Mast Therapeutics, Inc. from January 2013 to April 2017, and as its Senior Vice President, Finance, from March 2011 to January 2013. Previously, she held senior positions at Alphatec Spine, Inc., Artes Medical, Inc., Stratagene Corporation, and Pfizer, Inc. Ms. Roberts currently serves as Chair of the Southern California Chapter of the Association of Bioscience Financial Officers and has served on the Board of Temple Therapeutics BV since November 2019. Ms. Roberts is a certified public accountant with the State of California and received her B.S. degree in business administration from the University of Arizona and her M.B.A. from the University of San Diego.


Appointment of Chief Scientific Officer: In March, the Company announced the appointment of Anthony Hickey, Ph.D. as Chief Scientific Officer. Dr. Hickey is Professor Emeritus in Pharmacoengineering and Molecular Pharmaceutics at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill. Dr. Hickey is also Adjunct Professor of biomedical engineering at the University of North Carolina (UNC) School of Medicine.


Expanded Leadership Team: In March, the Company also announced the appointment of three additional seasoned executives to help lead the company:


John Koleng, Ph.D., R.Ph. - Vice President of Product Development and Manufacturing


Dr. Koleng has more than 20 years of experience in the pharmaceutical industry. He was an executive with three drug development companies, Oticara, Via Therapeutics, and CloXero Therapeutics, and co-founded AlphaVektor, LLC and Axxis Innovations, Inc. John is an industry-recognized expert in drug development including nasal/pulmonary products and injectables. John previously served as a consultant to TFF and is an inventor on several patent applications filed on behalf of TFF. He has a B.S. in Pharmacy and a Ph.D. in Pharmaceutics, both from the University of Texas at Austin where he currently is an Adjunct Assistant Professor of Pharmaceutics and serves on the College of Pharmacy Dean’s Advisory Council. He is a registered pharmacist.


Greg J. Davenport, Ph.D. - Vice President of Government and Strategic Initiatives Dr. Davenport brings over 28 years of pharmaceutical product development and government contracting experience as a C-Level Executive in the life sciences. Greg is a founding partner of Dport Federal Group, LLC, a consulting firm that assists various clients in the life science and pharmaceutical industries seeking to conduct business with the Federal Government. At TFF, Dr. Davenport oversees academic, government, and industry infectious disease and biodefense collaborations, while also pursuing non-dilutive funding to advance TFF’s technology platform and products to address government and commercial needs. Greg earned a B.S. from Dillard University and received his Ph.D. in Molecular Biology from Howard University.





Paul Manley - Head of Regulatory Affairs


Mr. Manley has accumulated 30+ years of business and senior management experience in regulatory affairs, compliance and overall drug development across a range of therapeutic areas. Paul’s corporate career encompasses senior management and technical leadership positions within the U.S. and Europe in both large corporations (VP, Global Regulatory Affairs – Oncology, Johnson & Johnson) and start-ups (VP, Regulatory Affairs and Compliance, Genta Incorporated). In 2007, Paul established Orvieto Consulting, LLC, providing strategic advice to numerous companies across a wide range of scientific disciplines.


Strategic Business Development and Partnership Activities – Biopharmaceutical Companies and Research Institutions:


● In May, the Company announced multiple presentations highlighting the broad applicability of its Thin Film Freezing Technology at the Respiratory Drug Delivery Meeting (RDD)


● In April, the Company announced safety and pharmacokinetic data from its Phase 1 study of Niclosamide Inhalation Powder, which is being developed as a potential treatment for COVID-19. The data showed that Niclosamide Inhalation Powder was well tolerated with no serious adverse events across all subject cohorts.


● In March, TFF entered into a collaboration agreement with Catalent focused on providing access to the innovative TFF technology to Catalent’s large number of clients, which has the potential to increase the adoption of the pulmonary and nasal route for the systemic delivery of biotherapeutics. In addition, Catalent will become the CDMO of choice for these referred clients and Catalent will assume a priority position in collaborations using TFF’s proprietary process for biologic drug manufacturing.


● In February, announced that results from its recently completed in vitro neutralization and viral replication assays indicate that the Niclosamide Inhalation Powder completely inhibited viral replication of both the Delta and Omicron variants of SARS-CoV-2. Compared to data from previously published studies, the results demonstrate that Niclosamide Inhalation Powder appears to be the most potent inhibitor of SARS-CoV-2 replication, including the Omicron variant. Results from these studies also confirm previous findings which validated the potent antiviral efficacy of Niclosamide in a human airway model.


In January, announced the completion of enrollment of 40 healthy subjects for a Phase 1 clinical trial (NCT#05168644) of Niclosamide Inhalation Powder.


The Company is developing Niclosamide Inhalation Powder in partnership with Union Therapeutics as a potential antiviral treatment to treat COVID-19 and other respiratory viral diseases.





Strategic Business Development and Partnership Activities – Governmental and Defense Contracting Agencies:


● In March, entered into a new Cooperative Research and Development Agreement with the United States Army Medical Research Institute of Infectious Diseases, also known as USAMRIID, and the Geneva Foundation, a nonprofit foundation that supports and advances innovative medical research within the U.S. Military. TFF Pharmaceuticals and USAMRIID will evaluate the immune response of a dry powder recombinant Vesicular Stomatitis Virus - Severe Acute Respiratory Syndrome Coronavirus-2 Glycoprotein vaccine formulated using TFF’s Thin Film Freezing technology. The end goal is to develop a single, easily administered and temperature stable countermeasure to protect our warfighters against multiple viral pathogens such as SARS-CoV-2, Ebola, and Marburg.


Financial Results


For the quarter ended March 31, 2022, compared to quarter ended March 31, 2021


Cash Position: As of March 31, 2022, TFF Pharmaceuticals reported cash and cash equivalents of $26.4 million.


Research and Development (R&D) expenses: R&D expenses for first quarter of 2022 were $5.3 million, compared to $5.3 million in 2021.


General & Administrative (G&A) expenses: G&A expenses for the first quarter of 2022 were $3.2 million, compared to $2.6 million in 2021.


Net Loss: TFF Pharmaceuticals reported a net loss for the first quarter of 2022 of $8.4 million, compared to a net loss of $7.7 million in 2021.




TFF Pharmaceuticals’ Thin Film Freezing (TFF) platform was designed to improve the solubility and absorption of poorly water-soluble drugs and is particularly suited to generate dry powder particles with properties targeted for inhalation delivery, especially to the deep lung, an area of extreme interest in respiratory medicine. The TFF process results in a “Brittle Matrix Particle,” which possesses low bulk density, high surface area, and typically an amorphous morphology, allowing the particles to supersaturate when contacting the target site, such as lung tissue.


Based upon laboratory experiments the aerodynamic properties of the particles are such that the portion of a drug deposited to the deep lung has the potential to reach as high as 75 percent.




TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform. Early testing confirms that the TFF platform can significantly improve the solubility and absorption of poorly water-soluble drugs, a class of drugs that comprises approximately one-third of the major pharmaceuticals worldwide, thereby improving their pharmacokinetics. TFF Pharmaceuticals has two lead drug candidates: Inhaled Voriconazole Powder and Inhaled Tacrolimus Powder. The Company plans to add to this pipeline by collaborating with large pharmaceutical partners. The TFF Platform is protected by over 120 patents issued or pending in the U.S. and internationally. To learn more about TFF Pharmaceuticals and its product candidates, visit the Company’s website at https://tffpharma.com.







This press release contains forward-looking statements regarding TFF Pharmaceuticals, Inc., including the expectations for its continued development of Inhaled Tacrolimus and Voriconazole Powders and an Inhaled Niclosamide Powder for the treatment of COVID-19 infection, collaboration and referral arrangement with Catalent, the benefits of the Company’s TFF platform and the Company’s plans to add to its existing pipeline of product candidates. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the Company may not be able to successfully conclude clinical testing or obtain pre-market approval of its Inhaled Tacrolimus, Voriconazole or Niclosamide Powders or any of its dry powder product candidates, (ii) the risk that the Company may not achieve the favorable results expected from its collaboration and referral agreement with Catalent, ((iii) no drug product incorporating the TFF platform has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (iv) the Company has no current agreements or understandings with any large pharmaceutical companies for the development of a drug product incorporating the TFF Platform, (v) the risk that the Company will not be able to conclude a long-term commercial agreement with any third-party, and (vi) those other risks disclosed in the section “Risk Factors” included in the Company’s 2021 Annual Report on Form 10-K filed with the SEC on March 24, 2022. TFF Pharmaceuticals cautions readers not to place undue reliance on any forward-looking statements. TFF Pharmaceuticals does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law.


Company Contacts:


Glenn Mattes

President and CEO

TFF Pharmaceuticals, Inc


Kirk Coleman

Chief Financial Officer

TFF Pharmaceuticals, Inc.



Investor Relations Contact:


Corey Davis, Ph.D.

LifeSci Advisors




Media Contact:


Gwendolyn Schanker

LifeSci Communications

(269) 921-3607





1Denning DW, Pleuvry A, Cole DC. Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. Med Mycol. 2013 May;51(4):361-70. doi: 10.3109/13693786.2012.738312. Epub 2012 Dec 4. PMID: 23210682. Accessed November 5, 2021.










   Three Months Ended   Three Months Ended 
   March 31,   March 31, 
   2022   2021 
Grant revenue  $67,435   $24,315 
Operating expenses:          
Research and development   5,261,604    5,278,252 
General and administrative   3,246,195    2,647,415 
Total operating expenses   8,507,799    7,925,667 
Loss from operations   (8,440,364)   (7,901,352)
Other income:          
Other income   57,177    231,278 
Interest income   7,185    15,499 
Total other income   64,362    246,777 
Net loss  $(8,376,002)  $(7,654,575)
Net loss per share, basic and diluted  $(0.33)  $(0.33)
Weighted average common shares outstanding, basic and diluted   25,371,781    23,140,607 








   March 31,   December 31, 
   2022   2021 
Current assets:        
Cash and cash equivalents  $26,414,170   $33,794,672 
Receivable due from collaboration agreement   1,776,583    1,628,703 
Research and development tax incentive receivable   1,168,830    966,646 
Prepaid assets and other current assets   2,164,451    2,447,930 
Total current assets   31,524,034    38,837,951 
Property and equipment, net   2,258,738    1,859,860 
Total assets  $33,782,772   $40,697,811 
Current liabilities:          
Accounts payable  $2,028,779   $1,493,842 
Accrued compensation   -    416,910 
Deferred research grant revenue   168,000    50,000 
Total liabilities   2,196,779    1,960,752 
Commitments and contingencies          
Stockholders’ equity:          
Common stock   25,372    25,372 
Additional paid-in capital   105,256,670    104,078,968 
Accumulated other comprehensive loss   (1,687)   (48,921)
Accumulated deficit   (73,694,362)   (65,318,360)
Total stockholders’ equity   31,585,993    38,737,059 
Total liabilities and stockholders’ equity  $33,782,772   $40,697,811